AstraZeneca finds no evidence of increased blood clots

The audit included more than 17 million people vaccinated in the European Union and Great Britain, the statement said.

The careful analysis of all available security data from more than 17 million people vaccinated in the EU and Great Britain with AstraZeneca vs. COVID-19 has shown no evidence of an increasing risk of pulmonary emboly, deep verebesis, or trombocytopenia”, the company points out.

Such risks “were not found in any set age group, or in any gender group, in any series of vaccines or elsewhere,” is said next in the statement.

About 17 million people in the EU and Great Britain have taken our vaccine to date, and the number of confirmed blood clotting in that population is less than the hundreds expected in the general population”, said a statement signed by Director Anne Taylor.

Taylor notes that due to the subx0 nature of pandemic, increased attention to individual cases” and that standards measures have been implemented for public health safety.

Italy's northern region of Piemte announced on Sunday that it is temporarily suspending the vaccine with AstraZeneca following the death of a teacher from the town of Bijelo, after it was vaccinated on Saturday.

Italy has thus joined a group of at least five European countries that have temporarily banned vaccines with the AstraZeneca vaccine.

Denmark, Norway and Iceland have banned vaccines due to blood clotting problems, and Austria stopped using a specific series of AstraZeneca vaccines last week while investigating a blood clotting death.

Ireland joined on Sunday because of its care, citing reports by the Norwegian Bars Agency on cases of blood clotting in some cases.

The European Barnas Agency has determined that there are no indicators of a cause link, which was repeated by the World Health Organization on Friday.